Introduction
============

PAD is a manifestation of atherosclerotic vascular disease. Epidemiology studies show a total prevalence of 3%--10%, which rises in the elderly over an age of 70 years to 15%--20%.[@b1-dddt-11-2937]--[@b3-dddt-11-2937] Due to a steadily aging society and a growing number of patients with comorbidities such as diabetes, hypercholesterolemia, and renal insufficiency, the number of patients with a PAD is expected to further increase,[@b4-dddt-11-2937] thus causing growing costs for the health care system.

In addition, PAD is an independent indicator of cardiovascular morbidity and mortality;[@b5-dddt-11-2937]--[@b8-dddt-11-2937] both mortality and amputation risk are growing in parallel with Rutherford stage (\>63% chance of amputation within 4 years in Rutherford stage 6).[@b9-dddt-11-2937] Thus, prevention and adequate treatment of PAD is of crucial importance. Besides controlling cardiovascular risk factors, the optimization of blood flow by endovascular treatment or vascular operation is a central pillar of PAD care.

Endovascular treatment has gained increasing importance in recent years.[@b3-dddt-11-2937] Different endovascular techniques are available for the management of peripheral stenosis and/or occlusions. Standard interventional treatment options besides POBA are DCBs, BMSs, and DESs, as well as numerous atherectomy devices. In addition, stent implantation increases the patency rate compared to POBA and probably also to DCB, thus being often used particularly in long and/or calcified lesions.[@b10-dddt-11-2937],[@b11-dddt-11-2937]

DAPT upon endovascular stenting is universally accepted to prevent subsequent thrombotic complications. However, the exact period of time in which a combination treatment of aspirin and clopidogrel should be applied upon stenting varies immensely among different centers. The current study aimed to compare whether the duration of DAPT has an impact on bleeding events, restenosis, patency, ischemic events, all-cause mortality, and amputation upon stent implantation in the iliac artery and SFA during a follow-up of 12 months. Patients were divided into 2 groups according to DAPT regime: a short (4--6 weeks) and a prolonged (8--12 weeks) group.

Patients' collective and methods
================================

Study design
------------

The current investigation is a nonrandomized, retrospective monocentric study. A total of 261 endovascular SFA and iliac stenting procedures had been performed on 214 patients at the Department of Cardiology, Angiology and Pneumology, University Hospital Heidelberg, between 2004 and 2016. Patients with more than 1 intervention were only included in the current study, if the second intervention was performed on the other lower extremity and not in the 12-month observation period of the first intervention. Follow-up examinations including clinical visit, ABI measurement, as well as Doppler sonography of the affected limb were performed immediately after, as well as 1, 3, 6, and 12 months after, the intervention. The study was approved by the local ethical committee at the University Hospital Heidelberg as a part of the Heidelberg Registry for PAD (S-331/2013) and was performed in accordance with the ethical requirements as stated in the Declaration of Helsinki. Informed consent was waived by the local ethics committee due to the retrospective design of the study. Since only the responsible physicians had access to non-anonymized patient data, absolute confidentiality of patient information was ensured.

The selection of the antiplatelet therapy duration was dependent on the interventionalist who approved the indication for an angiography. One interventionalist always used the prolonged regime, while the others primarily used the short-term antiplatelet therapy regime. The interventions were performed together to exclude a bias of the experience of the interventionalist.

Safety end points were defined as any procedure-dependent local vascular complication: arteriovenous fistula, aneurysm, and local bleeding in the area of the puncture side; in addition to that, systemic bleeding, compartment syndrome, and ischemic events (stroke, TIA) upon a 12-month follow-up were evaluated. Efficacy end points included clinical-relevant restenosis, patency, all-cause mortality, and amputation.

Primary patency was defined as freedom from significant restenosis of target lesion (\>50% reocclusion) as measured by Doppler ultrasound during a 12-month follow-up. Secondary patency resembled patency of the target lesion after (re)occlusion intervention of the index lesion.

Clinical symptoms of the patients included in the study were evaluated in terms of the Rutherford classification used for staging patients with PAD.[@b12-dddt-11-2937] Stage 0 includes asymptomatic patients. Depending on the symptoms, PAD patients were classified in mild (stage 1), moderate (stage 2), or severe (stage 3) stage. Stage 4 PAD patients had rest pain, and stage 5 and 6 ulcerations.

Lesion calcification assessment
-------------------------------

Assessment of target lesion characteristics was performed by 4 independent examiners (CE, MK, MA, and IS). Low calcification grade was defined as no or only isolated plaques, up to 50% circumferential lumen constringency by a plaque was defined as moderate, and \>50% was referred to as severe.

Interventional treatment methods
--------------------------------

All patients received an intraarterial bolus of 2500 IU heparin after a 6F sheath placement. During intervention, all patients received additional 2500 IU heparin. After crossing the culprit lesion with a guide wire, the lesions were dilated with an adequate balloon diameter for the treated vessel, followed by a BMS implantation. An optimal balloon pressure is elemental to break calcified lesions, to achieve long-term patency, and to treat dissection without the risk of artery wall perforation.

The decision for stent implantation was made by the interventionalists after angiography, depending on the extension of the occlusion, presence of recoil due to severe calcification, or blood flow limiting dissection. The type of stent depended on the preference of the interventionalists. All patients received 500 mg aspirin during the intervention and 300 mg clopidogrel after stent implantation at the end of the procedure. Out of 261 cases, 175 received a short-term antiplatelet therapy (4--6 weeks), and 86 a prolonged DAPT regime (8--12 weeks) of aspirin (100 mg/daily) and clopidogrel (75 mg daily).

Statistical analysis
--------------------

Chi-square tests were used to compare categorical data. Continuous variables were represented as mean ± SD. *t*-Test was used to compare means when variables were normally distributed. Kaplan--Meier curves were drawn to present survival data, and log-rank tests were used to assess differences in time-to-event end points. *P*-values of \<0.05 were considered statistically significant. Data analysis was performed using IBM SPSS, version 22.0 software.

Results
=======

Patient characteristics
-----------------------

A total of 214 patients underwent 261 consecutive interventional revascularization procedures including endovascular stenting of the SFA and iliac arteries between 2004 and 2016 at the Department of Cardiology, Angiology and Pneumology, University Hospital Heidelberg.

General data of the patients' collective including gender, age, weight, and height, as well as relevant cardiovascular risk factors and comorbidities, are summarized in [Tables 1](#t1-dddt-11-2937){ref-type="table"} and [2](#t2-dddt-11-2937){ref-type="table"}. In both groups, the majority of patients were admitted with the leading diagnosis of chronic progressive claudication (duration of symptoms was more than 2 weeks), corresponding to Rutherford stage 2--3 ([Table 3](#t3-dddt-11-2937){ref-type="table"}). The rest of the patients had acute or subacute symptoms (claudication, palor, skin ulceration), with duration of less than 2 weeks. In short DAPT and prolonged DAPT groups, 16.0% and 17.4% of patients, respectively, received additional long-term anticoagulation therapy mostly due to preexisting atrial fibrillation or thrombotic nature of the arterial occlusion, or within the frame of a conservative therapy attempt ([Table 3](#t3-dddt-11-2937){ref-type="table"}).

Lesion characteristics and safety of the interventional procedure
-----------------------------------------------------------------

The majority of patients in both groups displayed mild-to-moderate calcification (69.1% vs 66.2%, [Table 4](#t4-dddt-11-2937){ref-type="table"}), and most of the lesions were characterized by a significant length: 12.9±9.7 and 14.4±8.1 cm, respectively, ([Table 4](#t4-dddt-11-2937){ref-type="table"}). Percutaneous transluminal angioplasty was performed in the vast majority (89.7% short DAPT group, 97.7% prolonged DAPT group, ns, [Table 4](#t4-dddt-11-2937){ref-type="table"}) with a corresponding balloon pressure of an average 10.1±4.4 bar. The prolonged DAPT group had a significantly longer cumulative balloon dilatation time of 58.5 seconds compared to 41.5 seconds of the short DAPT group (*P*\<0.05, [Table 4](#t4-dddt-11-2937){ref-type="table"}).

Safety of the interventional procedure during follow-up of 12 months
--------------------------------------------------------------------

In our patients' collective, during the follow-up period of 12 months, a total of 18 severe bleeding occasions occurred: n=13 (7.4%) in the short DAPT group and n=5 (5.8%) in the prolonged DAPT group (1 intracranial, 1 compartment, 1 relevant intramuscular hematoma \[thigh\], 15 gastrointestinal). No difference was seen between the groups ([Figure 1](#f1-dddt-11-2937){ref-type="fig"}). Notably, only 4 out of 18 patients with relevant bleeding had received concomitant anticoagulation. Moreover, minor bleeding and/or periprocedural-dependent local vascular complication took place 4.6% in the short- and 5.8% in the long-term DAPT (*P*\>0.05, [Table 4](#t4-dddt-11-2937){ref-type="table"}). Peripheral embolizations occurred in only 2 patients (0.8%).

A total of 14 patients in the short and 7 in the prolonged DAPT group had a history of stroke/TIA ([Table 2](#t2-dddt-11-2937){ref-type="table"}). In addition, during the follow-up of 12 months, 6 (3.4%) patients in the short-term and 3 (3.5%) in the long-term DAPT regime suffered a stroke/TIA with no statistical difference ([Figure 1](#f1-dddt-11-2937){ref-type="fig"}).

Primary and secondary patency
-----------------------------

Twelve months after endovascular stenting of the SFA and the iliac vessels, there was no difference in primary patency in both groups (83.9% vs 79.8%, *P*\>0.05, [Figure 2A and B](#f2-dddt-11-2937){ref-type="fig"}), irrespective of the length and/or calcification grade of the treated stenosis or occlusion (data not shown). Secondary patency was \>90% in both groups, showing no difference between the short and prolonged DAPT treatment regimes (*P*\>0.05, [Figure 3](#f3-dddt-11-2937){ref-type="fig"}). Notably, the patients with or without anticoagulation did not differ between primary and secondary patency, amputation, and all-cause mortality.

No difference between the DAPT regimes in the prevention of major end points
----------------------------------------------------------------------------

Kaplan--Meier analysis was performed in order to trace overall and amputation-free survival during a 1-year follow-up ([Figure 4A and B](#f4-dddt-11-2937){ref-type="fig"}). A total of 4 patients died in the short and 2 in the prolonged DAPT group (*P*\<0.05); none of the death cases were related to the endovascular procedure. The causes of death were prolonged cardiogenic shock in 4 cases, acute arteria cerebri media infarction in 1 case, and metformin-induced lactate acidosis in acute-on-chronic renal failure (1 case).

Amputations occurred in 3 cases (1 patient in the short and 2 in the prolonged DAPT group, *P*\>0.05): In only 1 case, the amputation was performed due to a postinterventional complete thrombotic occlusion of the lower extremity, resistant to lysis and further endovascular revascularization treatment. A second major amputation needed to be performed due to a super-infection and a beginning sepsis of a patient with a Rutherford stage 4. A third amputation was performed at an external hospital, and no information was available regarding the exact reason for amputation.

By separating the patients' collective according to the lesion location, iliac vessels, and SFA, the study demonstrated no difference between the groups in terms of primary and secondary patency, amputation, all-cause mortality, and ABI measurement.

Substantial ABI improvement upon intervention in both groups
------------------------------------------------------------

Prior to intervention, both patient groups presented with significantly reduced ABI values: 0.6±0.2 and 0.6±0.2. Immediately after intervention, the ABI values significantly improved (0.9±0.2 and 0.8±0.2, *P*\<0.05). These results remained stable and significantly better than before the intervention over the next 12 months (*P*\<0.05, respectively, [Figure 5](#f5-dddt-11-2937){ref-type="fig"}).

Discussion
==========

Despite the increasing number of patients receiving endovascular stent due to a progressive PAD, the knowledge regarding postinterventional management, and more specifically DAPT after stent implantation, is still markedly limited. The DAPT used in clinical routine is mainly extrapolated to data on DAPT after coronary artery interventions.[@b13-dddt-11-2937],[@b14-dddt-11-2937]

Heiss et al published a randomized trial of 199 patients after angioplasty in the femoropopliteal location.[@b15-dddt-11-2937] The patients were divided into 3 groups, dipyridamol 75 mg together with a high ASS dosage of 330 mg or a low ASS concentration of 100 mg or placebo. The study demonstrated that dipyridamol 75 mg plus ASS 330 mg showed a significantly better patency compared to placebo. No difference was seen for dipyridamol 75 mg plus ASS 100 mg vs placebo. Another prospective, double-blind study with 223 patients investigated DAPT after iliofemoral angioplasty upon a 12-month follow-up.[@b16-dddt-11-2937] The patients were grouped into dipyridamol 400 mg together with ASS 50 mg and placebo. The study found no difference between the groups. Only in the iliac artery, the placebo group had more interventions. Tepe et al provided the only prospective, randomized, double-blind placebo-controlled clinical trial so far that investigated antiplatelet therapy after peripheral artery BMS implantation in a cohort of 80 patients.[@b17-dddt-11-2937] The study compared mono treatment of aspirin vs DAPT of aspirin plus clopidogrel. An advantage for DAPT vs aspirin alone was found in terms of TLR (2 vs 8 patients, *P*=0.04), but was not associated with increased minor bleeding complications. However, due to the limited number of patients and TLR, the usage of molecular surrogates as primary end points (local concentrations of platelet activation markers β-thromboglobulin and CD40L), and the observation period of only 6 months, the informative value as well as the clinical relevance of this study is significantly limited. In our cohort, we compared different DAPT regimes in terms of their safety and efficacy upon BMS implantation. To the best of our knowledge, this is the first study comparing the duration of DAPT after peripheral artery stent implantation. The study showed no difference in terms of primary and secondary patency, amputation, survival, and clinical outcome between both groups. In addition, major safety end points did not differ between both treatment regimes. Thus, 4 weeks of DAPT after BMS implantation seems to be not inferior in a real-world patient collective.

Different interventional treatment options are available for the atherosclerotic diseased iliac and femoral arteries. POBA is increasingly being replaced by DCB with significantly higher patency rates and a DAPT regime of at least 4 weeks.[@b18-dddt-11-2937]--[@b22-dddt-11-2937] Primary patency of the published studies was on average 80%--90% in short and primarily mildly calcified lesions. However, DCB seems to be less effective in complex stenosis as shown by Schmidt et al with primary patency of 53% after 24 months.[@b11-dddt-11-2937] Several studies investigated peripheral artery stent implantation outcome after 12 months with a DAPT therapy regime of 4--6 weeks. The re-intervention rate in complex lesions was 14.2% in the Supera stent-, 28.3% in the EverFlex-, 14.9% in the EPIC self-expanding nitinol stent-, and 18.3% in the SMART-study.[@b23-dddt-11-2937]--[@b26-dddt-11-2937] Furthermore, drug-coated stent studies revealed low re-intervention rates with a TLR of 4% in the MAJESTIC trial (single arm) and 9.5% in the Zilver PTX trial.[@b27-dddt-11-2937],[@b28-dddt-11-2937] The treated lesions in the reported studies were predominantly short (\~7 cm), whereas most of the lesions in the present study were both longer and of a moderate-to-severe calcification grade ([Table 4](#t4-dddt-11-2937){ref-type="table"}) that could possibly explain a re-intervention rate of 16% in the short-term and 23.5% in the long-term DAPT regime group. Taking the results from previous reports and our present study into consideration, BMS implantations appear to be a valuable treatment option in patients with symptomatic peripheral artery stenosis, both in short and in long calcified lesions.

Antiplatelet therapy is generally recommended for all patients with PAD to improve event-free survival, both as a primary and secondary prevention measure upon endovascular interventions.[@b29-dddt-11-2937]--[@b33-dddt-11-2937] The available data regarding safety and efficacy of different antiplatelet agents in the treatment of PAD are very heterogeneous. Recently, 3 publications aimed to investigate the impact of ticagrelor in PAD patients.[@b34-dddt-11-2937]--[@b36-dddt-11-2937] Ticagrelor is known to have beneficial effects in patients with an acute coronary syndrome and as a secondary prevention in patients with CAD.[@b37-dddt-11-2937],[@b38-dddt-11-2937] In patients with a PAD after a myocardial infarction, DAPT with ticagrelor and aspirin vs aspirin reduced the rate of cardiovascular mortality, stroke, and myocardial infarction.[@b36-dddt-11-2937] However, it remains to be elucidated whether ticagrelor and aspirin is superior to clopidogrel alone, since clopidogrel alone showed a significant risk reduction of 23.8% for cardiovascular complications and bleeding compared to aspirin in patients with PAD and CAD in the CAPRIE trial.[@b32-dddt-11-2937] In addition, in symptomatic PAD patients with and without an intervention, Hiatt et al demonstrated that ticagrelor vs clopidogrel showed no advantages regarding the composite end point of cardiovascular death, myocardial infarction, or ischemic stroke.[@b35-dddt-11-2937],[@b36-dddt-11-2937] Focused on ischemic stroke, the study demonstrated a significant reduction in the ticagrelor vs clopidogrel group (1.9% vs 2.4%).[@b35-dddt-11-2937] Thus, based on the large studies with different effects of ticagrelor in CAD and PAD patients, it appears that both diseases have 2 different entities and the results of studies in the field of CAD should be interpreted with caution, when transferred to PAD.

Limitations
===========

There are several limitations in the current study. First, the current study is a monocentric, nonrandomized retrospective registry; thus, results need to be interpreted carefully. In addition, only a limited number of selected patients with primarily complicated lesions were included; thus, the data cannot be transferred to other lesion characteristics and patients' collectives. Moreover, we investigated patients upon endovascular stenting; thus, the data cannot be extrapolated to patients upon normal angioplasty, DCB, DES, or atherectomy. Furthermore, we evaluated the different lesion locations, iliac artery and SFA, with known divergent outcomes within 1 study.

However, the main focus of the current study was safety and efficacy in a real-world patients' collective; in our collective, we could detect no significant differences upon stenting of the iliac vessels vs stenting of the SFA -- neither in terms of safety and efficacy, nor in terms of outcome; those results did not change over the years (2004--2010) vs (2011--2016).

Conclusion
==========

The current study provides a first rationale comparison between short- and long-term DAPT regime after BMS implantation in peripheral arteries. Short DAPT seems to be not inferior to prolonged DAPT regime in terms of safety and efficacy after peripheral interventions with BMS implantation in a 12-month follow-up, but additional studies are needed to further investigate these findings.
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![Kaplan--Meier analysis of combined safety end points 12 months upon revascularization (systemic bleeding, as well as ischemic events such as stroke/TIA).\
**Notes:** Bleeding in the short DAPT group is indicated by the solid green line, and in the prolonged DAPT group by the solid blue line. Stroke/TIA in the short DAPT group is indicated by the dotted green line, and in the prolonged DAPT group by the dotted blue line. All *P*-values are \>0.05.\
**Abbreviations:** TIA, transient ischemic attack; DAPT, dual antiplatelet treatment.](dddt-11-2937Fig1){#f1-dddt-11-2937}

![Kaplan--Meier analysis of primary patency 12 months upon index revascularization, separated according to lesion location: (**A**) iliac vessels and (**B**) SFA.\
**Notes:** Short DAPT group is indicated by the solid green line, and prolonged DAPT group by the solid blue line. *P*-values are \>0.05 for both.\
**Abbreviations:** SFA, superficial femoral artery; DAPT, dual antiplatelet treatment.](dddt-11-2937Fig2){#f2-dddt-11-2937}

![Kaplan--Meier analysis of secondary patency 12 months upon primary revascularization.\
**Notes:** Short DAPT group is indicated by the solid green line, and prolonged DAPT group by the solid blue line. *P*\>0.05.\
**Abbreviations:** SFA, superficial femoral artery; DAPT, dual antiplatelet treatment.](dddt-11-2937Fig3){#f3-dddt-11-2937}

![(**A**) Overall survival 12 months upon primary revascularization was analyzed using Kaplan--Meier.\
**Notes:** Short DAPT group is indicated by the solid green line, and prolonged DAPT group by the solid blue line. *P*\>0.05. (**B**) Kaplan--Meier analysis of amputation-free survival 12 months upon primary revascularization. Short DAPT group is indicated by the solid green line, and prolonged DAPT group by the solid blue line. *P*\>0.05.\
**Abbreviation:** DAPT, dual antiplatelet treatment.](dddt-11-2937Fig4){#f4-dddt-11-2937}

![ABI measurements before, immediately after, as well as 1, 3, 6, and 12 months after intervention.\
**Notes:** Short DAPT group is indicated by the green bars, and prolonged by the blue bars. Bar graph represents mean + SD. ^\*^*P*\<0.05.\
**Abbreviations:** ABI, ankle--brachial index; DAPT, dual antiplatelet treatment.](dddt-11-2937Fig5){#f5-dddt-11-2937}

###### 

Major demographic characteristics of the study population in terms of gender, age, weight, and height (n=214 patients)

  Patients' characteristics   Total        4--6 weeks   8--12 weeks   *P*-value
  --------------------------- ------------ ------------ ------------- -----------
  Male, n (%)                 143 (66.8)   95 (66.4)    48 (60.6)     \>0.05
  Female, n (%)               71 (33.2)    48 (33.6)    23 (32.4)     
  Age, mean ± SD (years)      68.7±9.6     67.9±9.2     70.1±9.0      \>0.05
  Weight, mean ± SD (kg)      78.1±15.4    77.5±15.1    79.1±15.8     \>0.05
  Height, mean ± SD (cm)      170.9±8.6    171.2±8.2    170.2±8.9     \>0.05
  BMI (kg/m^2^)               27.0         27.0         27.3          \>0.05

**Abbreviation:** BMI, body mass index.

###### 

Major cardiovascular risk factors and comorbidities (n=214 patients)

                                                   Total        4--6 weeks   8--12 weeks   *P*-value
  ------------------------------------------------ ------------ ------------ ------------- -----------
  Smoking (active and history of smoking), n (%)   132 (61.7)   85 (61.6)    47 (61.9)     \>0.05
  Arterial hypertension, n (%)                     179 (83.6)   112 (81.6)   67 (88.2)     \>0.05
  Diabetes, n (%)                                  82 (38.3)    46 (33.3)    36 (47.4)     \>0.05
  Coronary artery disease, n (%)                   96 (44.9)    64 (46.4)    32 (42.1)     \>0.05
  COPD, n (%)                                      21 (9.8)     5 (6.6)      16 (11.6)     \>0.05
  Atrial fibrilation, n (%)                        22 (10.3)    7 (9.2)      15 (10.9)     \>0.05
  Creatinine, mean ± SD (mg/dL)                    1.4±1.5      1.3±15       1.5±1.5       \>0.05
  Urea, mean ± SD (mg/dL)                          45.6±26.9    46.1±31.0    44.8±19.8     \>0.05
  History of stroke/TIA, n (%)                     21 (8.0)     14 (8.0)     7 (8.4)       \>0.05

**Abbreviation:** TIA, transient ischemic attack.

###### 

Symptom characterization in terms of Rutherford stage, duration of symptoms, and anticoagulation prior to revascularization (n=261 cases)

                                        Total        4--6 weeks   8--12 weeks   *P*-value
  ------------------------------------- ------------ ------------ ------------- -----------
  Rutherford stage, n (%)                                                       \>0.05
   2                                    157 (60.2)   105 (60.0)   52 (60.5)     
   3                                    92 (35.3)    64 (36.6)    28 (32.6)     
   4                                    4 (1.5)      2 (1.1)      2 (2.3)       
   5                                    4 (1.5)      2 (1.1)      2 (2.3)       
   6                                    4 (1.5)      1 (0.6)      3 (3.1)       
  Symptoms' duration \>2 weeks, n (%)   171 (65.5)   116 (66.3)   55 (63.9)     \>0.05
  Anticoagulation, n (%)                43 (16.5)    28 (16.0)    15 (17.4)     \>0.05

###### 

Target lesion characterization: localization, extension, grade of calcification, presence of thrombotic occlusion, PTA, and corresponding mean duration of dilatation and balloon pressure, as well as major peri-interventional complications

                                                                                Total        4--6 weeks   8--12 weeks   *P*-value
  ----------------------------------------------------------------------------- ------------ ------------ ------------- -----------
  Target lesion iliac artery, n (%)                                             63 (24.1)    44 (25.1)    19 (22.1)     \>0.05
  Target lesion SFA, n (%)                                                      214 (82.0)   134 (76.6)   69 (80.2)     \>0.05
  Length of occlusion, mean ± SD (cm)                                           13.6±9.0     12.9±9.7     14.4±8.1      \>0.05
  Total occlusion, n (%)                                                        115 (44.1)   78 (44.6)    37 (37.2)     \>0.05
  Calcification score, n (%)                                                                                            
   None                                                                         17 (6.5)     5 (2.9)      12 (14.0)     \>0.05
   Mild                                                                         90 (34.5)    58 (33.1)    32 (37.2)     \>0.05
   Moderate                                                                     88 (33.7)    63 (36.0)    25 (29.0)     \>0.05
   Severe                                                                       57 (21.8)    45 (25.7)    12 (14.0)     \>0.01
  Thrombotic occlusion, n (%)                                                   24 (9.2)     13 (7.7)     11 (12.8)     \>0.05
  PTA, n (%)                                                                    241 (92.3)   157 (89.7)   84 (97.7)     \>0.05
  Balloon pressure, mean ± SD (bar)                                             10.1±4.4     10.5±4.6     9.8±4.2       \>0.05
  Balloon dilatation time, mean ± SD (seconds)                                  50.0±40.1    41.5±26.0    58.5±54.1     \>0.05
  Minor bleeding, periprocedural-dependent local vascular complication, n (%)   13 (5.0)     8 (4.6)      5 (5.8)       \>0.05
  Peri-interventional embolization, n (%)                                       2 (0.8)      2 (1.1)      0 (0.0)       \>0.05
  Hospitalization duration, mean ± SD (days)                                    1.5±2.0      1.4±1.6      1.7±2.3       \>0.05

**Abbreviations:** PTA, percutaneous transluminal angioplasty; SFA, superficial femoral artery.
